Patents
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
12/2010
12/01/2010CN101214335B Externally-applied emplastrum for treating hyperosteogeny, protrusion of lumbar disc and arthritis
12/01/2010CN101204571B Edible Chinese traditional medicine composite for diabetes mellitus and preparation method thereof
12/01/2010CN101199617B Chinese medicine compound of fully natural green body beauty and producing method thereof
12/01/2010CN101171006B Film coated preparation
12/01/2010CN101167991B Burn and scald treating ointment
12/01/2010CN101167925B Traditional Chinese medicine for treating epistaxis caused by lung and gastric heat excess
12/01/2010CN101167924B Method for producing traditional Chinese medicine preparation of six ingredients with rehmannia
12/01/2010CN101155578B Medicament combination
12/01/2010CN101129373B Method for preparing Imiquimod chitosannano granule
12/01/2010CN101125123B Red sage root A magnesium injection preparation and preparation method thereof
12/01/2010CN101112511B Chinese traditional medicine gelling agent for treating laryngopharynx gall
12/01/2010CN101069746B Composition containing sugar-reducing medicine and antiplatelet medicine
12/01/2010CN101066422B Chinese medicine capsule for treating hysteromyoma and its preparation
12/01/2010CN101066126B Health food suitable for middle aged and old women
12/01/2010CN101028474B Method for inspecting the quality of Chinese preparation with Yang-and kidney tonifying functions
12/01/2010CN101019950B Qingkailing Preparation for great transfusion and its preparation process
12/01/2010CN101019904B Notoginseng dripping pill for treating coronary heart disease
12/01/2010CN101019872B Nanometer antiviral liposome medicine and its preparation
12/01/2010CN101007035B Application of notoginseng glycol saponins for treating memory deterioration
12/01/2010CN101007013B Liposome of astragaloside IV and its medicinal preparation
12/01/2010CN100998697B Lozenge made of traditional Chinese medicine for treating throat disease, and its preparing method
11/2010
11/30/2010US7842791 Dispersible pharmaceutical compositions
11/30/2010US7842730 includes rapidly excretable perfluororganic compounds e.g. perfluordecalin, perfluoractilbromide, a perfluoroganic additive embodied in the form of a mixture of perfluorinated tertiary amines contains perfluorotripropylamine and coproducts; and phospholipids in the form of a water-salt dispersion
11/30/2010US7842706 Pharmaceutical composition
11/30/2010US7842377 comprises alginates; anticancer agents; therapeutic vascular occlusions (embolizations)
11/30/2010US7842329 comprising a sorbent food body and a fluid carrier; enhanced caloric content and simulates the appearance of meat; moisture-reduced food product
11/30/2010US7842312 rapamycin in crystalline form encapsulated in at least one biocompatible polymer, at least 95 percent of the rapamycin in such composition is crystalline, the crystals being in the range from about 100 nanometers to about 200 nanometers.; for sustained release of drug; stability
11/30/2010US7842311 for oral dosage; for treatment of pain; sustained release
11/30/2010US7842310 Pharmaceutical compositions in particulate form
11/30/2010US7842309 Tamper-resistant oral opioid agonist formulations
11/30/2010US7842308 novel formulation or composition of a pharmaceutically acceptable polymer and suitable excipients to be used for injection molding of the capsules or multi-component dosage forms
11/30/2010US7842307 Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
11/30/2010US7842303 Biocompatible and biostable polyurethane based devices for the sustained delivery of drugs or other compounds in a living organism; produce local or systemic pharmacological effects
11/30/2010US7842302 adding, during preparation of the emulsion, a surfactant and a cosurfactant, the cosurfactant being an amphiphilic polymer having one or more hydrophobic and hydrophilic subunits, hydrophobic block are made of living polymerization of polyisobutylene to obtain double bond at the terminal
11/30/2010US7842294 useful in vaccine compositions for treatment of cancer; human major histocompatibility complex (MHC) Class I restricted peptides; kits
11/30/2010US7842287 tablet including an adsorbent such as activated carbon or silica gel or a mixture, potassium carbonate, polyvinylpyrrolidinone, and potassium bicarbonate; for use in computer and electronic devices
11/30/2010US7842284 Odor eliminating items and methods of use for hunting
11/30/2010US7842283 use in sclerotherapy of blood vessels; from a device, injecting a mixture of blood dispersible gases carbon dioxide and/or oxygen, and a sclerosing agent polidocanol, foaming in blood veins; avoiding use of potentially hazardous amounts of nitrogen; treating varicose veins disorder; drug delivery device
11/30/2010US7842282 use in sclerotherapy of blood vessels; from medical device, injecting a mixture of blood dispersible gases carbon dioxide and/or oxygen, and a sclerosing agent polidocanol, foaming in blood veins; avoiding use of potentially hazardous amounts of nitrogen; treating varicose veins disorder; drug delivery
11/30/2010US7842232 sterilized dispersions exhibit excellent chemical and physical stability, homogeneity, and uniformity
11/30/2010CA2577288C Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
11/30/2010CA2575957C Process for preparing a medicament
11/30/2010CA2559640C Means for transdermal administration of nicotine
11/30/2010CA2480123C Highly aqueous liquid carrier formulations
11/30/2010CA2473038C Weight management system for obese animals
11/30/2010CA2449352C Nsaid formulation comprising a granular composition and an extra-granular composition
11/30/2010CA2446768C Prosthetic foot with tunable performance
11/30/2010CA2420691C Wound preparations comprising an aqueous gel
11/30/2010CA2412804C Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives
11/30/2010CA2396129C Method and formulation for treating resistance to antihypertensives and related conditions
11/30/2010CA2362932C Pharmaceutical composition containing proton pump inhibitors
11/30/2010CA2326653C Compositions and methods of adjusting steroid hormone metabolism through facilitated absorption of hydrophobic dietary compounds
11/25/2010WO2010135736A2 Application and uses of prg4 and therapeutic modulation thereof
11/25/2010WO2010135396A2 Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
11/25/2010WO2010135053A2 Dual and single layer dosage forms
11/25/2010WO2010134988A1 Wound treatment systems, devices, and methods using biocompatible synthetic hydrogel compositions
11/25/2010WO2010134965A1 Solid pharmaceutical compositions and processes for their production
11/25/2010WO2010134942A1 Electrostatically charged multi-acting nasal application, product and method
11/25/2010WO2010134938A1 Modified release niacin pharmaceutical formulations
11/25/2010WO2010134904A1 Oral compositions containing polyguanidinium compounds and methods of manufacture and use thereof
11/25/2010WO2010134846A1 Substituted 8-sulfonyl-2,3,4,5-tetrahydro-1h-gamma-carbolines, ligands and pharmaceutical composition; method for the production and use of same
11/25/2010WO2010134804A1 Device and methods for enhanced multi-delivery of biologically active substances into an organism and to prevent local irritation
11/25/2010WO2010134676A1 Composition comprising the purified extract of bee venom for preventing and treating degenerative brain diseases
11/25/2010WO2010134614A1 SELF-EMULSIFYING COMPOSITION OF ω3 FATTY ACID
11/25/2010WO2010134574A1 Orally disintegrating tablet
11/25/2010WO2010134556A1 Aqueous injection solution containing 5-methyl-2-(1-piperazinyl)benzenesulfonic acid derivative
11/25/2010WO2010134540A1 Dry-coated orally-disintegrating tablet
11/25/2010WO2010134537A1 Cell membrane-permeable peptides
11/25/2010WO2010134433A1 Transdermal preparation
11/25/2010WO2010134097A2 Stable pharmaceutical compositions of olanzapine and process for their preparation
11/25/2010WO2010134087A1 Water dispersible glyceryl monooleate magnetic nanoparticle formulation
11/25/2010WO2010134074A1 Compositions for continuous administration of dopa decarboxylase inhibitors
11/25/2010WO2010134047A2 Liquid dosage forms of isotretinoin
11/25/2010WO2010134025A2 Oral compositions of celecoxib
11/25/2010WO2010133975A2 Reducible polyamino disulfides as transfectants
11/25/2010WO2010133961A1 Extended release compositions of cyclobenzaprine
11/25/2010WO2010133907A1 Hexadentate chelators in inflammatory bowel disease
11/25/2010WO2010133761A1 Intravaginal delivery system comprising one or more therapeutically active substances capable of preventing and/or treating vaginal infections
11/25/2010WO2010133757A1 Vaginal delivery system
11/25/2010WO2010133700A1 Pharmaceutical composition comprising microbubbles for targeted tumor therapy
11/25/2010WO2010133638A1 Pharmaceutical oral telmisartan solution
11/25/2010WO2010133629A1 Stable pharmaceutical composition of fludarabine phosphate
11/25/2010WO2010133611A1 Solid drug dispersions
11/25/2010WO2010133609A2 Composition comprising oil drops
11/25/2010WO2010133590A1 Pharmaceutical compositions for n-[2-(diethylamino)ethyl]-5-[(fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide
11/25/2010WO2010133374A2 Therapeutic composition comprising microspheres
11/25/2010WO2010133211A1 Decolorized extracts of the plant pandanus conoideus
11/25/2010WO2010133016A1 Pharmaceutical composition for treating depression, preparation method and use therefor
11/25/2010WO2010133015A1 Pharmaceutical composition for treating depression and preparative method and use thereof
11/25/2010WO2010133009A1 A anti-tumor chinese drugs preparation comprising lucidum spores oil and preparation method thereof
11/25/2010WO2010113177A3 Oral insulin delivery systems for controlling diabetes
11/25/2010WO2010107185A3 Composition for skin regeneration, containing a secretion in the culture of an embryonic stem cell-derived endothelial progenitor cell or fractions thereof, and use thereof
11/25/2010WO2010104485A3 Valsartan formulations
11/25/2010WO2010093523A3 Foamable microemulsion compositions for topical administration
11/25/2010WO2010093452A3 Reducible polymers for non-viral gene delivery
11/25/2010WO2010092590A3 Process for the preparation of doxorubicin liposomes
11/25/2010WO2010090765A3 Intrathecal baclofen pharmaceutical dosage forms with fewer degradation products
11/25/2010WO2010089760A3 Controlled release, multiple unit pharmaceutical compositions
11/25/2010WO2010088185A3 Matte skin finish compositions
11/25/2010WO2010082785A3 Oral pharmaceutical composition